Interestingly, recent studies indicate that JAK/STAT inhibitors, such as tofacitinib, significantly moderate the symptoms of rheumatoid arthritis and reduce the progression of osteoclasts as well as structural joint damage57. This evidence concerns the gene SOAT1 and rheumatoid arthritis.